Search results
ProQR has published the top-line results from its Phase 2/3 “Illuminate” trial of the RNA therapy sepofarsen for Leber congenital amaurosis type 10 caused by a specific mutation in the CEP290 gene.
Our partnerships are mutually beneficial. For Retina UK this means we can fund more research and offer support on a local level, while our partners can achieve corporate social responsibility objectives whilst making a tangible impact.
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.
A round-up of the latest research into inherited retinal conditions - February 2024.
Whether you are looking for practical information or emotional support, online, by phone or face-to-face, we’re here to help.
In spring 2021, the US company jCyte announced detailed results from their successful phase 2b clinical trial of jCell, a stem cell-based treatment for RP.
Thursday 15 May 2025, 7.00pm - 8.00pm - via Zoom - Come and join us for our latest meeting where we will be joined by our guest speakers and new sponsors, EMVI - A Mobile Visual Assistant Designed by and for the Visually Impaired.
Despite the knock-on effects of the pandemic, there’s been a lot going on this year in the world of research! Here are snapshots of a few stories that have appeared in the Research News section of our website in 2022.
Charities representing blind and partially sighted people are urging the UK Government to increase benefits in line with inflation rather than wages, when a decision is made at the end of the month.
Lynda Cantor was a founder member of the charity in 1975 and one of our original trustees
